Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | F10 | P00742 | 6/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2267301 | 0.98 | PKM (0.71) | PKMMAPTUSP2F10KDM1A | |
| Hydrochloric Acid SCHEMBL6195901 | 0.93 | PKM (0.64) | PKMMAPTUSP2F10MCOLN3 | |
| Trifluoroacetic Acid SCHEMBL6199635 | 0.89 | PKM (0.59) | PKMMAPTUSP2F10KDM1A | |
| SCHEMBL333988 | 0.84 | PKM (1.00) | PKMMAPTMCOLN3TSHRMEN1 | |
| SCHEMBL654548 | 0.84 | MAPT (1.00) | PKMMAPTUSP2ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL932094 | 0.83 | PKM (0.97) | PKMMAPTMCOLN3TSHRMEN1 | |
| Hydrochloric Acid SCHEMBL3253197 | 0.82 | MAPT (0.96) | PKMMAPTUSP2ALDH1A1MEN1 | |
| SCHEMBL2266915 | 0.82 | PKM (0.73) | PKMMAPTF10MCOLN3TSHR | |
| SCHEMBL4942386 | 0.81 | F10 (0.70) | PKMUSP2F10F2TSHR | |
| SCHEMBL654409 | 0.81 | MEN1 (0.73) | PKMMAPTUSP2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312214-B2 | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1307444-B1 | SUBSTITUTED HETEROCYCLIC AMIDES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1505966-A4 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-0986551-B1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-6936610-B2 | Heterocyclic derivatives | ASTRAZENECA UK LIMITED (GB) | 2005-08-30 | — | — | US | disclosed |
| EP-1505966-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1082303-B1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | ASTRAZENECA AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
| US-20040097491-A1 | Substituted heterocyclic amides | HERRON DAVID KENT (US) | 2004-05-20 | — | — | US | disclosed |
| CN-1272107-A | Benzamidine derivatives as factor Xa inhibitors | MERCK PATENT GMBH (DE) | 2000-11-01 | — | — | CN | disclosed |
| EP-1025086-A1 | BENZAMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GmbH (DE) | 2000-08-09 | — | — | EP | disclosed |
| WO-2000039092-A1 | HETEROCYCLIC AMIDES AS INHIBITORS OF FACTOR Xa | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-1999057099-A1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | ASTRAZENECA AB (SE) | 1999-11-11 | — | — | WO | disclosed |
| WO-1999057112-A1 | REDUCED PARTICLE SIZE FORM OF 1-(6-CHLORONAPHTH-2- YLSULPHONYL) -4-[4-(4PYRIDYL) BENZOYL] PIPERAZINE | ASTRAZENECA AB (SE) | 1999-11-11 | — | — | WO | disclosed |
| EP-0937048-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1999-08-25 | — | — | EP | disclosed |
| EP-0925286-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| WO-1999016751-A1 | BENZAMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | disclosed |
| WO-1998006705-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | SERPINC1, PCSK9, PLAT | PKM 3108/4885MAPT 4263/4885USP2 4652/4885 |
| US-20040097491-A1 | Substituted heterocyclic amides | F12, F11, F8 | PKM 1610/4885MAPT 4238/4885USP2 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.